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1. Introduction
Alzheimer’s disease (AD) is an insidiously progressive severe presenile and senile dementia,
involving a number of cellular and biochemical mechanisms. AD affects millions of humans
as the most common cause of cognitive decline worldwide, in addition to being a main medical
challenge for aging population. From the clinical point of view, AD is mostly characterized by
age-dependent inexorably progressing cognitive decline, affecting memory primarily associ‐
ated with behavioral and mood disorders, which increasingly appear as the disease advances
[1]. From the neuropathological point of view, AD is mostly characterized by selective
neuronal loss [2, 3], marked synaptic alterations [4–6], morphological mitochondrial abnor‐
malities [7, 8], tau pathology [9] resulting in neurofibrillary tangles (NFT) composed of
hyperphosphorylated tau [10], inflammatory responses and by extracellular extensive deposits
of polymers of Aβ peptide, in the form of neuritic plaques, which are a main hallmark of AD
[11, 12]. These are dispersed in the neocortex, the hippocampus, and many subcortical
structures, which play an important role in cognition. In addition, AD is characterized
ultrastructurally by organelle pathology involving mostly the microtubules, the mitochondria,
and Golgi apparatus [13].
Most studies have revealed that the main pathological criteria for AD, namely the neuritic
plaques and neurofibrillary tangles, can account for 40%–70% of the cognitive impairment seen
in advanced age, though additional cerebrovascular changes [14, 15] contribute greatly in
plotting the dramatic profile of AD.
The two main hypotheses of AD - the amyloid cascade hypothesis, introduced in 1991 [16,
17] and the Tau protein hypothesis, are still subjects of extensive research and debate.The
production and accumulation of Aβ peptide, a pathogenic factor leading to AD development,
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are the result of the post-translational proteolysis of the APP [18], by concerted actions of β-
and γ-secretases [19].
The  amyloidogenic  pathway  for  APP  is  initiated  by  β-  site  amyloid  precursor  protein-
cleavage  enzyme  1  (BACE-  1),  resulting  in  the  generation  of  the  intermediate  product
sAPPβ  [20].  γ  -Secretase  activity  is  substantial  for  the  cleavage  of  the  transmembrane
domain,  releasing  the  Aβ peptide  and the  APP intracellular  domain.  Generation  of  Aβ
peptide  may  occur  in  the  endoplasmic  reticulum  (ER),  trans-Golgi  network  [21],  in
lysosomes and on the surface of the cell, whereas its intracellular accumulation has been
mostly detected in the majority of neurons in the endoplasmic reticulum, the mitochon‐
dria [22], the lysosomes, the multivesicular bodies, associated with synaptic pathology [23].
Many risk factors may affect APP protein metabolism and Aβ peptide production, mainly
in late-onset AD. In addition changes in cellular protein homeostasis and aspects of protein
folding or misfolding [24] are also linked to AD pathogenesis [25].
All the biochemical phenomena, which may occur within the spectrum of pathogenetic
mechanisms in Alzheimer’s disease affect the brain metabolic activity reasonably, since
increasing evidence from functional neuroimaging plead in favor of the global and regional
disruptions in brain metabolism in advanced cases of AD [26].
From the etiological point of view, it would be hypothesized that the multiple genetic loci [27,
28], associated with familial Alzheimer’s disease would plead in favor of the heterogeneity of
the disease and support the idea that the phenomenological profile of Alzheimer’s disease may
be the final consequence of various metabolic, neurochemical, and morphological alterations,
based on a broad genetic background [29]. Although the majority of familial or inherited AD,
which manifests at an early age, are often associated with mutations in AβPP [30], the
numerous sporadic ones, which manifests usually at later stages of the life, are proved to be
multifactorial, including induced expression of AβPP [31] by pathological stimuli, environ‐
mental factors, as well as deprivation of trophic factors. The eventual accumulation of Aβ
peptide at synaptic terminals may be associated with synaptic damage, resulting in cognitive
decline in patients with AD [32]. Moreover the increased risk of AD in sporadic cases,
whenever a maternal relative is afflicted with the disease, pleads reasonably in favor of a
maternally derived predisposition, which might be related to mutations of mitochondrial DNA
(mtDNA) [33, 34].
1.1. Mitochondria in Alzheimer’s disease
Mitochondria are highly dynamic ATP-generating organelles, which play an essential role in
many cellular functions, such as alteration of reduction-oxidation potential of cells, free radical
scavenging, intracellular calcium regulation and activation of apoptotic process. Mitochondria
are unique amongst cellular organelles, since they dispose their own, spiral, double-stranded
DNA (mtDNA), which is mostly inherited from the maternal line. The number of mitochondria
is very high in neurons and especially in synaptic terminals, since they are the major energy
generators for the cell biological processes and the synaptic activity, through tricarboxylic cycle
and oxidative phosphorylation. The shape and size of mitochondria are not stable, since they
undergo continual fission and fusion leading to their fragmentation or elongation accordingly.
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Mitochondrial dysfunction might contribute to Aβ neurotoxicity and is also associated with
oxidative stress, which may play an important role in the early stages of pathogenetic mech‐
anisms in AD [35-37], presumably prior to the onset of the cognitive dysfunction, since a
substantial body of evidence suggests that mitochondria play a crucial role in ageing-related
neurodegenerative diseases [38].
Mitochondria may be the target for amyloid precursor protein (APP) and Aβ peptide, which
might play an important role in impairing mitochondrial dynamics [39]. During AD processes
accumulation of APP occurs mostly in the mitochondrial import channels, inducing mito‐
chondrial functional impairment [40]. APP could not be processed to generate Aβ peptide
locally [41] although a fraction of active γ-secretase is associated with mitochondria [42].
In the mitochondria, Aβ peptide uptake is mediated by the translocase, which is located
in the outer mitochondrial membrane (TOM) [43]. Then Aβ peptide is accumulated mostly
in the outer mitochondrial  membrane,  the inter membrane and the matrix and interacts
with large number of  proteins  inside mitochondria,  leading eventually  to  mitochondrial
dysfunction,  whenever  substantial  amount  of  molecules  of  Aβ  peptide  would  be  pro‐
duced near mitochondria [44].
It is important to emphasize that mitochondrial alterations are associated with synaptic loss
in AD patients, even before amyloid plaques are detected [32, 45]. Morphological and mor‐
phometric studies revealed that at early stages of AD the number of mitochondria in synaptic
terminals is dramatically decrease and their structural pattern changes [45]. That modification
might be attributed to enhanced nitrosative stress, generated by Aβ peptide, leading to
mitochondrial fission, which is followed by mitochondrial depletion, resulting in synaptic
degeneration eventually [46].
1.2. Golgi apparatus in Alzheimer’s disease
Golgi apparatus plays an important role in the pathogenesis of AD [13, 47], since it is associated
with protein trafficking. All newly synthesized proteins, which are used for fast axoplasmic
transport are processed practically through the vesicles and the cisternae of Golgi complex [48].
From the first its visualization by Camillo Golgi, in 1898, Golgi apparatus has been subject of
intense morphological and neurochemical research.
The electron microscopy study of the mammalian Golgi apparatus has revealed that it consists
of stapled cisternae, which serve for the modification of newly synthesized proteins and lipids.
At the entrance site of the Golgi apparatus, namely the cis-Golgi, numerous clusters of vesicles
and tubular structures form an intermediate chain between the smooth endoplasmic reticulum
and the Golgi stack. The exit site, the so called trans-Golgi network (TGN) is the main site of
sorting proteins to distinct cellular destinations. Bi-directional traffic between the Golgi
apparatus and the endosomal system sustains the functions of the trans-Golgi network (TGN)
in secretion and organelle biogenesis [49].
The function of the Golgi complex consists mainly on vesicular transport, involving constant
membrane fission and fusion, mediated by GTPases, coat proteins, Rabs, tethers and SNARE
proteins, respectively, as it was documented from studies on glycosylation enzymes [50]. The
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activity of γ-secretase, which consists of presenilins (PSs) [51], nicastrin [52,53], pen-2 [54] and
the aph proteins [54,55], is closely related with the function of Golgi complex, since it requires
the presenilin-dependent trafficking of nicastrin, through the Golgi apparatus [56].
It was hypothesized that the passage of nicastrin and other components of the γ-secretase
complex through Golgi apparatus is essential for the molecular stabilization and the protease
activity [56]. In addition APP, which is normally synthesized in the endoplasmic reticulum
(ER), is transported to trans-Golgi network (TGN) for trafficking to the cell surface [57, 58], or
to synaptic terminals. APP is transported by fast axonal transport, been recycled back for
further trafficking or final storing within the lysosomal system [59], in view that TGN generates
transport vesicles bound for distinct domains of the plasma membrane and early endosomes.
Whereas a small proportion of APP molecules are delivered to the plasma membrane and then
cleaved by α-secretase into non-amyloidogenic fragments, the majority of APP molecules
undergo degradation, following amyloidogenic pathway in the trans-Golgi network [59].
2. Material and methods
2.1. Patients
We studied the hippocampus, the acoustic and the visual cortices, the thalamus, the globus
pallidus, the locus coeruleus, the red nucleus, the hypothalamus and many regions of the
cerebellar cortex in ten brains of patients who suffered from AD, four men and six women,
aged 62–87 years, who fulfilled the clinical, neuropsychological, and laboratory diagnostic
criteria of AD.
The mean education of the patients was 15.2 years, and all of them spoke their native language
fluently. Screening procedures were applied, which included medical history, medical
examination, cardiological investigation, physical neurologic assessment, psychiatric and
neuropsychological examinations. All the patients underwent EEG, carotid duplex Doppler,
computerized tomography (CT) scanning and magnetic resonance imaging (MRI) of the brain,
and single-photon emission computed tomography (SPECT).
The mental status of the patients was assessed by Mini mental State Examination (MMSE) and
dementia rating scale (DRS) [60] and ADAS-COX test.
The cause of death of the patients was heart arrest, following to cardiac infarct one to seven
months after the final neurological assessment. The postmortem examination of each one of
the cases was performed within 6 h after death.
2.2. Electron microscopy
Small samples (2×2×2 mm) from the hippocampus, the acoustic and the visual cortices, the
thalamus, the globus pallidus, the locus coeruleus, the red nucleus, the hypothalamus and
from many regions of the cortex of the cerebellar hemispheres and the vermis were excised
and immediately immersed in Sotelo’s fixing solution, composed of 1% paraformaldehyde,
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2.5% glutaraldehyde in cacodylate buffer 0.1 M, adjusted at pH 7.35. Then they were postfixed
by immersion in 1% osmium tetroxide for 30 min at room temperature and dehydrated in
graded alcohol solutions and propylene oxide.
Thin sections were cut in a Reichert ultratome, contrasted with uranyl acetate and lead citrate,
and studied in a Zeiss 9aS electron microscope.
We studied the morphology of the mitochondria, the Golgi apparatus, and the synapses and
we proceeded to morphometric estimations at electron microscope on micrographs of a
standard magnification of 56. 000 X.
2.3. Light microscope, Golgi staining, Golgi-Nissl method
The remaining parts of the above-mentioned areas of the brain and the cerebellum were
processed for silver impregnation techniques, according to rapid Golgi method.
Thus, after a four-week fixation in formalin they were immersed in potassium dichromate (7 
g potassium dichromate in 300 mL water) for 10 days. Then they were immersed in 1% silver
nitrate for 10 days. Following a rapid dehydration in graded alcohol solutions, the specimens
were embedded in paraffin and cut, some of them at 100 μ and some at 25 μ, alternatively.
Many sections of 25 μ were stained also with methylene blue, according to Golgi-Nissl method.
All the sections were mounted in permount, between two cover slips and were studied in a
Zeiss Axiolab Photomicroscope.
We estimated the dendritic arborization, the morphology and the number of the dendritic
branches, and the morphology of the dendritic spines in light microscope on sections stained
according to rapid Golgi and Golgi-Nissl methods
2.4. Statistical analysis
Statistical analysis was based on the t-test on the basis of 5000 mitochondria and 600 Golgi
apparatus from 30 specimens of AD brains and 30 specimens of normal control brains.
3. Results
3.1. Silver impregnation techniques
The silver impregnation technique or black reaction (reazione near) according to Golgi [61] is a
simple and easy histological procedure that enables the visualization of the three-dimensional
morphology of neurons and glial cells. Santiago Ramón y Cajal has been applying Golgi
technique extensively for the histological analysis of the CNS, defending successfully the
“neuron doctrine” and sharing with Camillo Golgi the Nobel Prize in 1906. After 140 years
from its first application, the Golgi technique continues to remain a very useful and valuable
method in neuropathology for the morphological and morphometric estimation of neuronal
circuits at the early stages of the degenerative processes of the brain [62].
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The application of silver impregnation technique in our specimens revealed neuronal loss and
marked abbreviation of the dendritic arborization in all the layers of the acoustic and the visual
cortices, the hippocampus, the thalamus, the globus pallidus, the locus coeruleus, the red
nucleus, the hypothalamus (Fig.1), the cerebellar cortex (Fig.2) and the vermis of the cerebel‐
lum (Fig.3). The layer I, of the acoustic and visual cortices, which includes Cajal-Retzius cells,
which normally protrude very long horizontal axonal profiles with substantial number of
collaterals [63. 64], was practically empty of neurons in patients who suffered from AD, in
contrast to normal controls.
Figure 1. Neuron from the Hypothalamus of a case of AD, showing abbreviation of dendritic arborization and marked
loss of dendritic spines (Golgi staining 2,400X)
Loss of tertiary dendritic branches was also noticed in the acoustic and visual cortices in all of
the specimens. Abbreviation of the dendritic arborization was mostly prominent in neurons
of layers III and V of the acoustic and visual cortices, the pyramidal neurons of the hippocam‐
pus, the polyhedral neurons of the locus coeruleus and in Purkinje cells of the cerebellar cortex,
which demonstrated also a marked decrease of the number of dendritic spines (Fig.3) in
comparison with the normal controls.
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Figure 3. Purkinje cells from the vermis of the cerebellum of a case of AD, showing dramatic reduction of dendritic
branches and loss of dendritic spines (Golgi staining 3,100X)
Figure 2. Purkinje cells from the cerebellar hemisphere of a case of AD, demonstrating marked abbreviation of the
dendritic arborization and considerable loss of dendritic spines (Golgi staining 2,000X).
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In addition, the axonal collaterals in layers III, IV, V, and VI of the acoustic and visual cortices
were dramatically decreased in comparison with the normal controls.
The decrease of the branches of the apical dendrites of the cortical neurons as well as decrease
in spine density was widespread phenomena seen in the large majority of neurons of the
acoustic (Fig.4) and the visual cortices, in the hippocampus, the thalamus, the globus pallidus,
the red nucleus, the locus coeruleus, the hypothalamus and the cerebellar cortex (Figs 1,2).
Figure 4. Neurons from the acoustic cortex of a case of AD, showing marked decrease of tertiary dendritic branches
and tremendous loss of spines (Golgi staining 2,400X).
3.2. Electron microscopy
Electron microscopy is the most valuable and precise method for the morphological and
morphometric study of the cell organelles, the synapses, the dendritic spines as well as the
neuron- glial relationships in the CNS both in health and disease.
In our study, the electron microscopy revealed pathological alterations of the dendritic spines
and impressive decrease in spine density in the secondary and tertiary dendritic branches in
all of the layers of the acoustic and visual cortices.
The reduction in spine size was prominent in neurons of layers II, III, and V of the acoustic
cortex. A substantial number of dendritic spines demonstrated large multivesicular bodies,
abnormal spine apparatus, and mitochondria, which were characterized by marked morpho‐
logical alterations. Morphological alterations of the dendritic spines were also seen in the
pyramidal neurons of the hippocampus, the large polyhedral neurons of the thalamus, the
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globus pallidus, the polyhedral neurons of the locus coeruleus as well as the Purkinje cells of
the cerebellar hemispheres (Fig.5). Giant elongated spines were mostly seen in the hippocam‐
pus and in the Purkinje cells of the cerebellum. In a large number of presynaptic terminals of
the acoustic and visual cortices of patients who suffered from AD, the ultrastructural study
has revealed an considerable polymorphism and pleomorphism of the synaptic vesicles, which
were dramatically decreased in number in comparison with normal controls.
Figure 5. Synaptic alterations in the cerebellar cortex in a case of AD. Impressive poverty of synaptic vesicles is noticed
at the presynaptic terminals associated with mitochondrial alterations and disruption of the spinal apparatus (Electron
micrograph 128,000X).
Substatial poverty of the synaptic vesicles was particularly seen in the presynaptic terminals
in layers III, IV, and V of the acoustic and visual cortices, as well as in the mossy fibers of the
cerebellar cortex. Decrease of the number of synaptic vesicles associated with polymorphism
of the remained vesicles was noticed in the hippocampus, the thalamus, the locus coeruleus,
and the parallel and climbing fibers of the cerebellar cortex.
Mitochondrial pathology was demonstrated in the majority of the dendritic spines in all of the
specimens. That consisted of substantial change of mitochondrial shape and size, fragmenta‐
tion of cristae, and accumulation of osmiophilic material in a considerable number of mitochon‐
drial profiles (Fig.6). Many dendritic branches included mitochondria, which showed an unusual
polymorphic arrangement of the cristae, which either showed a concentric configuration or they
were arranged in a parallel way to the long axis of the organelle. Some Purkinje cell dendrites
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(Fig.6) and a substantial number of climbing fibers included very large elongated mitochon‐
dria. Small round mitochondria intermixed with dense bodies were seen in association with
fragmentation or dilatation of the cisternae of the Golgi apparatus in the soma of a considera‐
ble number of neurons of the visual cortex (Fig.7), the hippocampus, the locus coeruleus, the red
nucleus, the polyhedral neurons of globus pallidus, and the Purkinje cells in AD brains.
Figure 6. Abnormal mitochondria in a dendritic profile of Purkinje cell in a case of AD. The disruption of the cristae is a
prominent phenomenon (Electron micrograph 128,000X).
Figure 7. Elongated mitocondria and mitochondria in fusión, intermixed with dense bodies and dilated cisternae of
Golgi apparatus in a case of AD (Electron micrograph 25,000X).
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It is worth to emphasize that morphological alterations of the mitochondria were also seen in
the soma of astrocytes, the perivascular processes, and the astrocytic sheaths in AD brains, in
contrast to normal controls.
From the morphometric point of view the ellipsoid mitochondria of the dendritic spines in
normal control brains appear to have an average diameter of 650 ± 250 nm and a mean axial
ratio of 1.9 ± 0.2. The round or global mitochondria appeared to have in normal controls a mean
radius of 350 nm. In AD brains, the ellipsoid mitochondria of the neurons in acoustic and visual
cortices appear to have an average diameter of 480 ± 250 nm and a mean axial ratio of 1.7 ± 0.2.
The round mitochondria appear to have a mean radius of 280 nm (Chart.1).
Chart 1. Decrease of the diameter of mitochondria in the visual cortex in Alzheimer’s cases in comparison with normal
controls.
In the majority of Purkinje cells of the cerebellum, in the hippocampal neurons and in neurons
of the parietal, frontal, acoustic and visual cortices the Golgi apparatus was mostly fragmented
and atrophic (Fig.8) in comparison with normal controls.
 
Figure 9. Fragmentation of the cisternae of the Golgi apparatus in a Purkinje cell of the cerebellar cortex of a case of
AD (left) (Electron micrograph 128,000). Normal control (right) (Electron micrograph 65,000X)
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It is important to underline that the fragmentation of the Golgi apparatus was seen in neurons
which did not showed any tau pathology, such as accumulation of intracellular NFTs, and
were located in areas with minimal deposits of Aβ peptide. However the atrophy and the
fragmentation of Golgi apparatus coexisted with mitochondrial alterations and dendritic and
spinal pathology in the large majority of neurons (Fig.9).
Figure 9. Degeneration of dendritic spine in the visual cortex of a case of AD (Electron micrograph 130,000X)
4. Discussion
The mitochondria, which are the only nonnuclear constituents of the cell with their own DNA
(mtDNA), having machinery for synthesizing RNA and proteins, are critical to homeostasis
of the cell, by virtue of providing most of the energy for cellular processes, since energy,
realized by oxidative phosphorylation, comes through the mitochondria, which generate most
of the cell’s supply of ATP. Mitochondria are also critical regulators of cell apoptosis, as being
involved in a considerable number of neurodegenerative diseases [65, 66],
From the morphological point of view the shape and size of the mitochondria are highly
variable  [67],  depending  on  fission  and  fusion  [68].  Their  morphology  is  occasionally
controlled by cytoskeletal elements, namely the neurofilaments and the microtubules [69].
The  change  of  the  mitochondrial  shape  occurs  mostly  through  their  move  to  axons,
dendrites,  and  synaptic  terminals  via  anterograde  transport  [70].  During  the  various
neuronal  processes  approximately  one-third  of  the  mitochondria  are  in  motion  along
microtubules  and  actin  filaments  [71–73].  Mitochondrial  motility  and  accumulation  are
coordinated, since mitochondria are transported to regions where ATP consumption and
necessity for energy are particularly high, as it  occurs in the synapses, which have high
energy demand reasonably, for serving neuronal communication [74].
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Mitochondrial alterations and dysfunction have been reported in several neurodegenerative
diseases [75] mostly associated with oxidative damage [76-78] and vascular lesions [79].
Oxidative stress is mostly related with the accumulation of Aβ peptide in the neocortex [80,
81], playing an important role in the pathogenesis of AD [82], since it is not only involved in
the formation of senile plaques and in damage to the proteins of NFT [83], but also induces
extensive damage to the cytoplasm of neuronal populations vulnerable to death [84].
It is also well documented that Aβ peptide may increase mitochondrial reactive oxygen species
(ROS) production [85, 86], causing further impairment of mitochondrial function [87], since
the lack of histones in mitochondrial DNA renders them a vulnerable target to oxidative stress.
In major examples of neurodegenerative diseases, there is strong evidence that mitochondrial
dysfunction occurs early and acts causally in disease pathogenesis. Mutations in mitochondrial
DNA and oxidative stress, on the other hand, may contribute to ageing [88, 89], which is the
substantial biological background for the majority of the neurodegenerative diseases [65].
Mitochondrial dysfunction has been associated with energy crisis of the cell and excitotoxic
cell death and is considered to be of substantial importance in the cascade of phenomena, which
eventually lead to apoptosis. Some observations in early cases of AD [90] indicate that
morphological alterations of the mitochondria and oxidative damage may be one of the earliest
events.
The morphological alteration of the mitochondria seen in subcortical centers, such as in the
thalamus, the globus pallidus, the red nucleus, the hypothalamus and the locus coeruleus,
pleads in favor of a generalized mitochondrial dysfunction in AD, which may be associated
with wide neuronal loss and synaptic alterations, seriously affecting the mental faculties,
which are basically related to extensive neural networks [91] and synaptic activity. Moreover,
an impressive number of disease-specific proteins interact with mitochondria. Well-docu‐
mented studies [92] demonstrate that a significant amount of the N-terminal domain of APP
targeted the mitochondria of cortical neurons and select regions of the brain of a transgenic
mouse model for AD. The accumulation of trans membrane-arrested APP blocked protein
translocation, disrupted mitochondrial function, and impaired brain energy metabolism.
In AD it may be considered that mitochondria-associated Aβ peptide may directly cause
neurotoxicity [93, 94]. Mitochondrial dysfunction, therefore, might be a hallmark of amyloid-
beta-induced neuronal toxicity in Alzheimer’s disease [95]. The binding site for amyloid beta
peptide has been identified as alcohol dehydrogenase in the matrix space of the organelle.
Recent evidence also suggest that PS1, PS2, APP, and γ-secretase activity are not homogene‐
ously distributed in the ER, but rather are enriched in mitochondria-associated ER membranes
(ER-MAMs or MAMs), which is a dynamic sub-compartment of the ER, which is connected
with mitochondria [96]. Mitochondria and ER are closely connected in several functions such
as transfer of Calium, lipid metabolism, the control of apoptosis and autophagy [96]
Many morphological alterations of AD could be well linked to mitochondria changes, since
blockage of mitochondrial energy production shifts APP metabolism to the production of more
amyloidogenic forms of amyloid [97]. In addition amyloid beta peptide promotes permeability
transition pore in brain mitochondria [85, 98]. It is important to mention that many protein
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systems are also essential in mitochondrial function and morphological integrity as well as in
binding to the cytoskeleton [99]. Mitochondrial porin is an outer-membrane protein that forms
regulated channels (Voltage-Dependent Anionic Channels) between the mitochondrial inter-
membrane space and the cytosol [100]. Porin may play an important role in binding to
neurofilaments and microtubules, since porin-rich domains contain most of the binding sites
for MAP2 [101, 102]. In addition, preselinin-2 modulates endoplasmic reticulum-mitochon‐
drial interactions [103], a fact that would plead in favor of the crucial role that mitochondria
play in the pathogenetic cascade of AD.
Recent studies reported increased mitochondrial fission and decreased fusion, due to increased
amyloid beta (Aβ) interaction with the mitochondrial fission protein Drp 1, inducing increased
mitochondrial fragmentation, impaired axonal transport of mitochondria and synaptic
degeneration in AD [104]. In addition, the interaction of the voltage-dependent anion channel
1 protein (VDAC1) with Aβ peptide and phosphorylated tau block mitochondrial pores,
leading to mitochondrial dysfunction in AD [105].
The number of the mitochondria varies, according to energy state of the cell. Some evidence
suggests that the mitochondria redistribute towards the dendritic profiles, in response to
stimulation as a manifestation of synaptic plasticity [106]. Normally, a limited number of
dendritic spines contain mitochondria, which are mostly small and round, which are increased
in number inside the dendritic branches during the synaptogenesis. Decrease in energy
metabolism and altered cytochrome c oxidase (CytOX) activity are among the earliest detect‐
able defects in AD [107], affecting presumably neuronal plasticity and synaptogenesis. Some
observations suggest that mitochondrial cytochrome c oxidase may be inhibited by a dimeric
conformer of Aβ35, a phenomenon which further emphasizes the role of the Aβ peptide on the
mitochondrial dysfunction in AD [108].
Among the ongoing therapeutic efforts [109], those targeting basic mitochondrial processes,
such as energy metabolism, free-radical generation, or specific interactions of disease-related
proteins with mitochondria, hold great promise. On the basis of the mitochondrial pathology,
in the pathogenetic spectrum in AD, new strategies inducing protection to mitochondria by
the administration of efficient antioxidant factors could be introduced in the treatment of early
cases of AD.
Golgi apparatus, on the other hand plays a very important role in posttranslational modifica‐
tions, transport, and targeting of large number of proteins, which participate in axoplasmic
transport or are transported to plasma membrane, to lysosomes, to synaptic terminals and
dendritic spines. A substantial body of evidence suggest that Golgi complex is involved in the
pathogenesis of amyotrophic lateral sclerosis (ALS) [110-112] and AD, as it is well documented
by highly specific immunocytochemistry techniques [47, 113].
The size of the Golgi apparatus may be an index of neuronal activity. Thus the fragmentation
of the cisternae of Golgi apparatus may be associated with impaired trafficking of proteins to
synapses and dendritic spines resulting in synaptic degeneration and cognitive impairment
eventually. It is well documented that the trans-Golgi network (TGN) is the major sorting
structure of the secretory pathway and the main site of intersection with the endo-lysosomal
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system [48, 49]. Current data clearly suggest that perturbations to the endosomal retrograde
sorting pathway promote the production of Aβ. The recent discovery of an integral membrane
protein, Gamma-secretase activating protein (GSAP) [114,115],which associates with γ-
secretase, APP and promotes the production Aβ peptide may provide an important link for
understanding how γ-secretase is directed to APP and help to clarify the site(s) of Aβ pro‐
duction. GSAP might be also an ideal target for designing γ-secretase modulators in an attempt
for treating AD [116,117].
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